How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Patient Risk Capital Investment Market
- By Investor Type: Venture Capital Firms, Private Equity Firms, Corporate Venture Arms, Family Offices, Angel Investors
- By Investment Stage: Seed Stage, Early Stage, Growth Stage, Late Stage, Mezzanine Financing
- By Therapeutic Area Focus: Oncology, Cardiovascular, Neurology, Infectious Diseases, Rare Diseases
- By Investment Instrument: Equity Financing, Convertible Notes, Preferred Stock, Debt Financing, Royalty Financing
- By Exit Strategy: Initial Public Offering (IPO), Merger and Acquisition (M&A), Secondary Sale, Buyback
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Venture Capital Firms leads By Investor Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Patient Risk Capital Investment Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Investor Type 5
Investment Stage 5
Therapeutic Area Focus 5
Investment Instrument 5
Exit Strategy 4
Companies profiled
Accel
Benchmark Capital
First Round Capital
Lowercase Capital
Sequoia Capital
UNION SQUARE VENTURES
Andreessen Horowitz
Bessemer Venture Partners
Greylock Partners
Kleiner Perkins Caufield & Byers
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Accel
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Benchmark Capital
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →First Round Capital
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Lowercase Capital
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sequoia Capital
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →UNION SQUARE VENTURES
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Andreessen Horowitz
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Bessemer Venture Partners
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Greylock Partners
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Kleiner Perkins Caufield & Byers
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,604M by 2033 · 6.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Venture Capital Firms45.0
- Private Equity Firms9.3
- Corporate Venture Arms18.1
- Family Offices16.1
- Angel Investors11.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,343M → $2,297M · 6.9%
Europe$936.3M → $1,593M · 6.9%
Asia Pacific$854.9M → $1,338M · 5.8%
Latin America$529.2M → $771.3M · 4.8%
Middle East and Africa$407.1M → $640.3M · 5.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.192026
6.202027
6.212028
6.222029
6.242030
6.242031
6.252032
6.272033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Accel10.3
- Benchmark Capital26.8
- First Round Capital4.8
- Lowercase Capital11.5
- Sequoia Capital5.3
- UNION SQUARE VENTURES13.2
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Investor Type25.7%
Investment Stage18.1%
Therapeutic Area Focus15.1%
Investment Instrument23.7%
Exit Strategy17.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.6
- Europe24.0
- Asia Pacific20.1
- Latin America11.6
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Accel | 84 | 78 | 75 | 95 | 95 | 87 | 86 |
| Benchmark Capital | 82 | 76 | 90 | 68 | 85 | 86 | 81 |
| First Round Capital | 71 | 72 | 67 | 66 | 66 | 82 | 71 |
| Lowercase Capital | 75 | 70 | 70 | 63 | 66 | 80 | 71 |
| Sequoia Capital | 72 | 69 | 63 | 64 | 54 | 54 | 63 |
| UNION SQUARE VENTURES | 68 | 68 | 62 | 57 | 53 | 47 | 59 |
| Andreessen Horowitz | 41 | 60 | 61 | 61 | 50 | 51 | 54 |
| Bessemer Venture Partners | 38 | 37 | 38 | 59 | 54 | 46 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Accel
- Benchmark Capital
- First Round Capital
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Accel | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Benchmark Capital | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| First Round Capital | ◐ | ◐ | − | − | ✓ | ✓ |
| Lowercase Capital | ◐ | − | ✓ | ◐ | ◐ | ✓ |
| Sequoia Capital | ◐ | ◐ | − | − | − | − |
| UNION SQUARE VENTURES | ◐ | − | ◐ | ◐ | ◐ | − |
| Andreessen Horowitz | − | ◐ | ◐ | ◐ | − | − |
| Bessemer Venture Partners | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Accel86
2Benchmark Capital81
3First Round Capital71
4Lowercase Capital71
5Sequoia Capital63
6UNION SQUARE VENTURES59
7Andreessen Horowitz54
8Bessemer Venture Partners45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
AccelBenchmark Capital
Challenger2
Strong scale, closing on the leaders.
First Round CapitalLowercase Capital
Contender2
Focused players with pockets of strength.
Sequoia CapitalUNION SQUARE VENTURES
Niche2
Specialists in a single segment or region.
Andreessen HorowitzBessemer Venture Partners
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Investor Type in North America, then scale across Patient Risk Capital Investment Market — a $290M beachhead inside a $5.12B market.
Beachhead (SOM)$290Mobtainable near-term
Serviceable (SAM)$1.96Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Venture Capital Firms
Best fit — highest urgency & budget in Investor Type.
Economic buyer76 fit
Private Equity Firms
Strong fit — clear ROI and a fast path to value.
End user65 fit
Corporate Venture Arms
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Investor Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Investment Stage & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapeutic Area Focus
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel29%
Digital / self-serve18%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Investor Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Patient Risk Capital Investment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified21%
Evaluation14%
Closed-won7%
$14.9KCAC
$82KLTV
5.5:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Patient Risk Capital Investment Market is a durable-growth opportunity — $7.54B by 2033, compounding at 6.2%.
TAM · 2025$4.67Btoday
TAM · 2033$7.54Bforecast
CAGR6.2%2027–2033
Cumulative$54.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.54BTotal addressable market
SAM$2.80BServiceable available market
SOM$537MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.2% CAGR
Demand compounds through 2033, outpacing GDP across Investor Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Investor Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.54BLarge & growingTAM by 2033 at 6.2% CAGR
$2.80BServiceable nowreachable with today’s model
$537MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.88BBear4.0% CAGR
$7.54BBase6.2% CAGR
$9.65BBull8.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Investment Stage optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Patient Risk Capital Investment Market — a $5.13B market by 2033. Plan: grow share from 10.4% to 16.9%.
Market size · 2033$5.13Btotal addressable
Market CAGR6.8%2027–2033
Target share16.9%from 10.4% today
Revenue ambition$868Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.4% | 16.9% | Behind |
| Revenue | $531M | $868M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 31.7% | 40.6% | At risk |
| Customer retention | 91.6% | 95.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Investor Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Investment Stage capability
A defensible second engine — invest in Investment Stage to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Investor Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Investment Stage
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $116M capacity & capability investment
- Greenlight bolt-on M&A in Investment Stage
- Authorise North America expansion plan
- Fund R&D program for Investor Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Patient Risk Capital Investment Market conversation — a $8.08B market you can size, segment and defend in minutes.
Market size · 2033$8.08Btotal opportunity
Growth4.9%CAGR to 2033
Addressable buyers1,129+accounts in scope
Typical ROI5.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Investor Type
Goal Grow share in Investor Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.5×return on cost, year one
< 4 mopayback period
$93K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
AccelBenchmark CapitalFirst Round CapitalLowercase CapitalSequoia CapitalUNION SQUARE VENTURESAndreessen HorowitzBessemer Venture Partners+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Patient Risk Capital Investment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Patient Risk Capital Investment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Implantable Blood Glucose Monitor Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportImplantable Biosensors Market
Market size, share, segmentation and regional forecast.
$773M market · 2025 base year
View reportImplantable Animal Chip Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportImplantable Air Conduction Hearing Aids Market
Market size, share, segmentation and regional forecast.
$460M market · 2025 base year
View reportImplantable Actuators Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportImpingement Freezer Market
Market size, share, segmentation and regional forecast.
$339M market · 2025 base year
View reportImpetigo Medicines Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportImpetiCbead (IMB) Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportImpermeable Spunlace Surgical Gown Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportDebt Recovery Solution Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportMedical Imaging Displays and Post-Processing Software Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportImpedance Head Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.